RT Journal Article
SR Electronic
A1 Vinall, Phil
T1 Patients Receiving Hemodialysis for Treatment of End-Stage Renal Disease Did Not Benefit from Statin Therapy: Results of the AURORA Trial
JF MD Conference Express
YR 2009
FD SAGE Publications
VO 9
IS 2
SP 14
OP 15
DO 10.1177/155989770902006
UL http://mdc.sagepub.com/content/9/2/14.abstract
AB Rosuvastatin did not improve cardiovascular morbidity and mortality in patients who had end-stage renal disease and who were on hemodialysis, according to results of the large, randomized, placebo-controlled A Study to Evaluate the Use of Rosuvastatin in Subjects On Regular hemodialysis: an Assessment of Survival and Cardiovascular Events [AURORA; NCT00240331] trial. There was no difference between rosuvastatin 10 mg and placebo in reducing the combined endpoint of cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction or any of the individual components of this endpoint when analyzed separately.